65.64 <%= Resources.Global.txtUp %>
Updated 14:33:31
Change % 0.55% Stock price increasing
Change 0.36 Stock price increasing
Volume 64,236
High 65.74
Low 65.18
Open 65.30
ISIN BE0003739530
Prev close 65.28
# of shares 194.51M
Market cap 12,767M EUR

Market is open (until 16:30) - Delayed 15 min
Price development Latest 1 week 1 month 3 months 6 months 1 year
  65.64 0.5% Stock price increasing 0.6% Stock price increasing -5.6% Stock price decreasing 6.7% Stock price increasing -8.3% Stock price decreasing
Powered by TradingView

Company profile

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's newer key drugs include Cimzia (rheumatoid arthritis, psoriatic arthritis, and Crohn's disease), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), and Briviact (epilepsy).

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
23 April 2018 14:48:43
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180423.5 - EUROWEB7 - 2018-04-23 15:48:43 - 2018-04-23 14:48:43 - 1000 - Website: OKAY